• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

口服羟吗啡酮治疗疼痛的综述。

Review of oral oxymorphone in the management of pain.

机构信息

University of Kentucky Medical Center, Department of Anesthesiology, Lexington, KY, USA.

出版信息

Ther Clin Risk Manag. 2008 Aug;4(4):777-87. doi: 10.2147/tcrm.s1784.

DOI:10.2147/tcrm.s1784
PMID:19209260
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2621383/
Abstract

Chronic cancer and nonmalignant pain (CNMP) is a common and major health problem afflicting approximately 40 million persons in the US. Most cancer patients, and many patients with CNMP, require opioid analgesics to obtain adequate pain relief. Oral oxymorphone is a new formulation of an existing parenteral opioid that has become available for the treatment of significant pain: acute postoperative, chronic arthritis, chronic low back, and chronic cancer pain. Oxymorphone is a typical mu-opioid agonist that is effective in both immediate- and extended-release (IR and ER) formulations. Oxymorphone is more lipid soluble than morphine, resulting in a rapid onset of action when given in tablet formulation, with a duration of action of approximately 4-6 hours in IR and 12 hours in ER preparations. Oxymorphone provides excellent pain relief for significant pain, with typical opioid side effects that are usually mild or moderate in intensity. Multiple double-blind, prospective, placebo-controlled clinical trials have demonstrated the clinical efficacy and safety of this new oral opioid preparation. Oral oxymorphone is an effective opioid that provides a new therapeutic option for the physician.

摘要

慢性癌症和非恶性疼痛（CNMP）是一种常见且严重的健康问题，影响了美国约 4000 万人。大多数癌症患者和许多患有 CNMP 的患者需要阿片类镇痛药来获得足够的疼痛缓解。口服羟吗啡酮是一种新的现有注射用阿片类药物的配方，已可用于治疗严重疼痛：急性术后、慢性关节炎、慢性下腰痛和慢性癌症疼痛。羟吗啡酮是一种典型的μ-阿片类激动剂，在即时释放（IR）和延长释放（ER）制剂中均有效。羟吗啡酮比吗啡更具脂溶性，因此在片剂制剂中起效迅速，IR 制剂的作用持续时间约为 4-6 小时，ER 制剂为 12 小时。羟吗啡酮能为严重疼痛提供良好的疼痛缓解，通常具有典型的阿片类药物副作用，其强度通常为轻度或中度。多项双盲、前瞻性、安慰剂对照临床试验已经证明了这种新的口服阿片类药物制剂的临床疗效和安全性。口服羟吗啡酮是一种有效的阿片类药物，为医生提供了一种新的治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e836/2621383/37aba7b88fb6/tcrm-4-777f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e836/2621383/e963adf8b60d/tcrm-4-777f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e836/2621383/403c7aa5f351/tcrm-4-777f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e836/2621383/491acbc04efc/tcrm-4-777f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e836/2621383/d029bea514dd/tcrm-4-777f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e836/2621383/98d20b75ba86/tcrm-4-777f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e836/2621383/37aba7b88fb6/tcrm-4-777f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e836/2621383/e963adf8b60d/tcrm-4-777f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e836/2621383/403c7aa5f351/tcrm-4-777f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e836/2621383/491acbc04efc/tcrm-4-777f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e836/2621383/d029bea514dd/tcrm-4-777f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e836/2621383/98d20b75ba86/tcrm-4-777f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e836/2621383/37aba7b88fb6/tcrm-4-777f6.jpg

相似文献

1
Review of oral oxymorphone in the management of pain.口服羟吗啡酮治疗疼痛的综述。
Ther Clin Risk Manag. 2008 Aug;4(4):777-87. doi: 10.2147/tcrm.s1784.
2
Use of oral oxymorphone in the elderly.老年患者口服羟考酮的应用。
Consult Pharm. 2007 May;22(5):417-30. doi: 10.4140/tcp.n.2007.417.
3
Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.羟吗啡酮速释片用于腹部手术后急性疼痛的疗效及耐受性：一项随机、双盲、活性药物与安慰剂对照的平行组试验。
Clin Ther. 2007 Jun;29(6):1000-12. doi: 10.1016/j.clinthera.2007.06.001.
4
Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.奥施康定控释片（羟考酮缓释片）用于缓解有阿片类药物使用经验患者的中度至重度慢性下腰痛的疗效和安全性：一项为期12周的随机、双盲、安慰剂对照研究。
J Pain. 2007 Feb;8(2):175-84. doi: 10.1016/j.jpain.2006.09.011. Epub 2006 Dec 4.
5
Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review.羟吗啡酮及羟吗啡酮缓释剂：药物治疗综述
J Opioid Manag. 2008 May-Jun;4(3):131-44. doi: 10.5055/jom.2008.0018.
6
A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.一项为期2周的多中心、随机、双盲、安慰剂对照、剂量范围研究的III期试验，比较了羟考酮缓释剂与安慰剂对患有髋部或膝部骨关节炎相关疼痛的成年人的疗效。
Clin Ther. 2006 Mar;28(3):352-64. doi: 10.1016/j.clinthera.2006.03.008.
7
Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.用于治疗慢性下腰痛的羟吗啡酮缓释剂：根据年龄、性别和既往阿片类药物使用情况分层的富集入组临床试验数据的回顾性汇总分析
Clin Ther. 2009 Feb;31(2):347-59. doi: 10.1016/j.clinthera.2009.02.019.
8
Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study.口服缓释羟考酮治疗癌痛的有效性和安全性：一项试点研究。
Support Care Cancer. 2005 Jan;13(1):57-65. doi: 10.1007/s00520-004-0731-1. Epub 2004 Nov 9.
9
A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain.一项为期12周的随机、安慰剂对照试验，评估羟吗啡酮缓释剂用于初用阿片类药物的慢性下腰痛患者的安全性和有效性。
Curr Med Res Opin. 2007 Jan;23(1):117-28. doi: 10.1185/030079906x162692.
10
Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.羟考酮缓释片治疗慢性下腰痛的疗效与安全性：一项随机、双盲、安慰剂对照及活性药物对照的III期研究结果
J Pain. 2005 Jan;6(1):21-8. doi: 10.1016/j.jpain.2004.09.005.

引用本文的文献

1
Structure based virtual screening and molecular simulation study of FDA-approved drugs to inhibit human HDAC6 and VISTA as dual cancer immunotherapy.基于结构的虚拟筛选和分子模拟研究 FDA 批准的药物抑制人 HDAC6 和 VISTA 作为双重癌症免疫疗法。
Sci Rep. 2023 Sep 2;13(1):14466. doi: 10.1038/s41598-023-41325-9.
2
The nociceptin/orphanin FQ receptor system as a target to alleviate cancer-induced bone pain in rats: Model validation and pharmacological evaluation.孤啡肽/痛敏肽FQ受体系统作为缓解大鼠癌症诱导性骨痛的靶点：模型验证与药理学评价
Br J Pharmacol. 2021 May;178(9):1995-2007. doi: 10.1111/bph.14899. Epub 2020 Jan 21.
3

本文引用的文献

1
Tramadol extended-release in the management of chronic pain.曲马多控释片治疗慢性疼痛。
Ther Clin Risk Manag. 2007 Jun;3(3):401-10.
2
Opioid use and abuse: is there a problem?阿片类药物的使用与滥用：这是个问题吗？
Clin J Pain. 2007 Oct;23(8):661-2. doi: 10.1097/AJP.0b013e31814b1d46.
3
Neuraxial pain relief for intractable cancer pain.用于顽固性癌痛的神经轴性疼痛缓解
A Surface-Enhanced Raman Spectral Library of Important Drugs Associated With Point-of-Care and Field Applications.
与即时护理和现场应用相关的重要药物的表面增强拉曼光谱库。
Front Chem. 2019 Oct 25;7:706. doi: 10.3389/fchem.2019.00706. eCollection 2019.
4
Adult cancer pain.成人癌症疼痛。
J Natl Compr Canc Netw. 2013 Aug;11(8):992-1022. doi: 10.6004/jnccn.2013.0119.
Curr Pain Headache Rep. 2007 Aug;11(4):283-9. doi: 10.1007/s11916-007-0205-5.
4
Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients.慢性疼痛患者从高剂量吗啡转换为透皮丁丙诺啡（Transtec）的阿片类药物轮换。
Pain Pract. 2007 Jun;7(2):123-9. doi: 10.1111/j.1533-2500.2007.00119.x.
5
Treatment of chronic pain in pediatric rheumatic disease.小儿风湿性疾病慢性疼痛的治疗
Nat Clin Pract Rheumatol. 2007 Apr;3(4):210-8. doi: 10.1038/ncprheum0458.
6
Oxycodone accumulation in a hemodialysis patient.一名血液透析患者体内的羟考酮蓄积情况。
South Med J. 2007 Feb;100(2):212-4. doi: 10.1097/01.smj.0000242876.45747.0a.
7
Ultra-low-dose opioid antagonists to enhance opioid analgesia.超低剂量阿片类拮抗剂增强阿片类镇痛作用。
J Opioid Manag. 2006 Sep-Oct;2(5):295-304. doi: 10.5055/jom.2006.0044.
8
A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain.一项为期12周的随机、安慰剂对照试验，评估羟吗啡酮缓释剂用于初用阿片类药物的慢性下腰痛患者的安全性和有效性。
Curr Med Res Opin. 2007 Jan;23(1):117-28. doi: 10.1185/030079906x162692.
9
Oral oxymorphone (Opana).
Med Lett Drugs Ther. 2007 Jan 1;49(1251):3-4.
10
Norman Cousins Lecture. Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids.诺曼·卡曾斯讲座。神经胶质细胞作为“反派”：对改善临床疼痛控制及阿片类药物临床效用的启示
Brain Behav Immun. 2007 Feb;21(2):131-46. doi: 10.1016/j.bbi.2006.10.011. Epub 2006 Dec 18.